New psoriasis drug tracked in real-world study: safe and effective?
NCT ID NCT05670821
First seen Nov 01, 2025 · Last updated Apr 30, 2026 · Updated 22 times
Summary
This study followed 52 Japanese patients with generalized pustular psoriasis (GPP) who received spesolimab for the first time. Researchers monitored side effects and how the disease behaved in everyday medical practice. The goal was to see how safe the drug is and how well it controls GPP symptoms outside of clinical trials.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GENERALIZED PUSTULAR PSORIASIS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Nippon Boehringer Ingelheim Co., Ltd.
Tokyo, 1416017, Japan
Conditions
Explore the condition pages connected to this study.